428 related articles for article (PubMed ID: 24711047)
21. Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson's disease.
Santos-García D; de la Fuente-Fernández R
J Neurol Sci; 2013 Sep; 332(1-2):136-40. PubMed ID: 23890935
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of Rotigotine at Different Stages of Parkinson's Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage.
Giladi N; Nicholas AP; Asgharnejad M; Dohin E; Woltering F; Bauer L; Poewe W
J Parkinsons Dis; 2016 Oct; 6(4):741-749. PubMed ID: 27567886
[TBL] [Abstract][Full Text] [Related]
23. Health-related quality of life in Parkinson disease: correlation between Health Utilities Index III and Unified Parkinson's Disease Rating Scale (UPDRS) in U.S. male veterans.
Kleiner-Fisman G; Stern MB; Fisman DN
Health Qual Life Outcomes; 2010 Aug; 8():91. PubMed ID: 20799993
[TBL] [Abstract][Full Text] [Related]
24. A double-blind, delayed-start trial of rasagiline in Parkinson's disease.
Olanow CW; Rascol O; Hauser R; Feigin PD; Jankovic J; Lang A; Langston W; Melamed E; Poewe W; Stocchi F; Tolosa E;
N Engl J Med; 2009 Sep; 361(13):1268-78. PubMed ID: 19776408
[TBL] [Abstract][Full Text] [Related]
25. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease.
Jankovic J; Hunter C
Parkinsonism Relat Disord; 2002 Mar; 8(4):271-6. PubMed ID: 12039422
[TBL] [Abstract][Full Text] [Related]
26. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
Parkinson Study Group CALM Cohort Investigators
Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
[TBL] [Abstract][Full Text] [Related]
27. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort.
Regnault A; Boroojerdi B; Meunier J; Bani M; Morel T; Cano S
J Neurol; 2019 Aug; 266(8):1927-1936. PubMed ID: 31073716
[TBL] [Abstract][Full Text] [Related]
28. Long-term impact on quality of life of subthalamic nucleus stimulation in Parkinson's disease.
Lezcano E; Gómez-Esteban JC; Tijero B; Bilbao G; Lambarri I; Rodriguez O; Villoria R; Dolado A; Berganzo K; Molano A; de Gopegui ER; Pomposo I; Gabilondo I; Zarranz JJ
J Neurol; 2016 May; 263(5):895-905. PubMed ID: 26964542
[TBL] [Abstract][Full Text] [Related]
29. Impact of 6-month earlier versus postponed initiation of rotigotine on long-term outcome: post hoc analysis of patients with early Parkinson's disease with mild symptom severity.
Timmermann L; Asgharnejad M; Boroojerdi B; Dohin E; Woltering F; Elmer LW
Expert Opin Pharmacother; 2015; 16(10):1423-33. PubMed ID: 25997442
[TBL] [Abstract][Full Text] [Related]
30. Trial of Lixisenatide in Early Parkinson's Disease.
Meissner WG; Remy P; Giordana C; Maltête D; Derkinderen P; Houéto JL; Anheim M; Benatru I; Boraud T; Brefel-Courbon C; Carrière N; Catala H; Colin O; Corvol JC; Damier P; Dellapina E; Devos D; Drapier S; Fabbri M; Ferrier V; Foubert-Samier A; Frismand-Kryloff S; Georget A; Germain C; Grimaldi S; Hardy C; Hopes L; Krystkowiak P; Laurens B; Lefaucheur R; Mariani LL; Marques A; Marse C; Ory-Magne F; Rigalleau V; Salhi H; Saubion A; Stott SRW; Thalamas C; Thiriez C; Tir M; Wyse RK; Benard A; Rascol O;
N Engl J Med; 2024 Apr; 390(13):1176-1185. PubMed ID: 38598572
[TBL] [Abstract][Full Text] [Related]
31. Predictors of weight loss in early treated Parkinson's disease from the NET-PD LS-1 cohort.
Wills AM; Li R; Pérez A; Ren X; Boyd J;
J Neurol; 2017 Aug; 264(8):1746-1753. PubMed ID: 28712000
[TBL] [Abstract][Full Text] [Related]
32. Asymmetric responsiveness of disability and health-related quality of life to improvement versus decline in Parkinson's disease.
Lamichhane D; Gruber-Baldini AL; Reich SG; Shulman LM
Qual Life Res; 2016 Dec; 25(12):3139-3145. PubMed ID: 27363693
[TBL] [Abstract][Full Text] [Related]
33. The Key Determinants to Quality of Life in Parkinson's Disease Patients: Results from the Parkinson's Disease Biomarker Program (PDBP).
He L; Lee EY; Sterling NW; Kong L; Lewis MM; Du G; Eslinger PJ; Huang X
J Parkinsons Dis; 2016 May; 6(3):523-32. PubMed ID: 27258700
[TBL] [Abstract][Full Text] [Related]
34. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.
Shults CW; Oakes D; Kieburtz K; Beal MF; Haas R; Plumb S; Juncos JL; Nutt J; Shoulson I; Carter J; Kompoliti K; Perlmutter JS; Reich S; Stern M; Watts RL; Kurlan R; Molho E; Harrison M; Lew M;
Arch Neurol; 2002 Oct; 59(10):1541-50. PubMed ID: 12374491
[TBL] [Abstract][Full Text] [Related]
35. Pingchan Granule for Motor Symptoms and Non-Motor Symptoms of Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Study.
Gu SC; Ye Q; Wang CD; Zhao SR; Zhou J; Gao C; Zhang Y; Liu ZG; Yuan CX
Front Pharmacol; 2022; 13():739194. PubMed ID: 35281890
[No Abstract] [Full Text] [Related]
36. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
Parkinson Study Group
JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
[TBL] [Abstract][Full Text] [Related]
37. Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients.
Martínez-Martín P; Rodríguez-Blázquez C; Forjaz MJ; Alvarez-Sánchez M; Arakaki T; Bergareche-Yarza A; Chade A; Garretto N; Gershanik O; Kurtis MM; Martínez-Castrillo JC; Mendoza-Rodríguez A; Moore HP; Rodríguez-Violante M; Singer C; Tilley BC; Huang J; Stebbins GT; Goetz CG
Eur J Neurol; 2014 Mar; 21(3):519-24. PubMed ID: 24447695
[TBL] [Abstract][Full Text] [Related]
38. Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial.
Patterson CG; Joslin E; Gil AB; Spigle W; Nemet T; Chahine L; Christiansen CL; Melanson E; Kohrt WM; Mancini M; Josbeno D; Balfany K; Griffith G; Dunlap MK; Lamotte G; Suttman E; Larson D; Branson C; McKee KE; Goelz L; Poon C; Tilley B; Kang UJ; Tansey MG; Luthra N; Tanner CM; Haus JM; Fantuzzi G; McFarland NR; Gonzalez-Latapi P; Foroud T; Motl R; Schwarzschild MA; Simuni T; Marek K; Naito A; Lungu C; Corcos DM;
Trials; 2022 Oct; 23(1):855. PubMed ID: 36203214
[TBL] [Abstract][Full Text] [Related]
39. The impact of depressive symptoms in early Parkinson disease.
Ravina B; Camicioli R; Como PG; Marsh L; Jankovic J; Weintraub D; Elm J
Neurology; 2007 Jul; 69(4):342-7. PubMed ID: 17581943
[TBL] [Abstract][Full Text] [Related]
40. Actigraphy monitoring of symptoms in patients with Parkinson's disease.
Pan W; Kwak S; Li F; Wu C; Chen Y; Yamamoto Y; Cai D
Physiol Behav; 2013 Jul; 119():156-60. PubMed ID: 23748129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
